AI OKTO Corp. filed a Form 6-K on November 3, 2026, disclosing that it began distributing a shareholder notice and accompanying election form related to a previously announced dividend expected to be paid on November 25, 2026.
Laurion Capital Management LP, along with co-managing members Benjamin Alexander Smith and Janaka Sheehan Maduraperuma, filed Amendment No. 3 to a beneficial ownership statement with the SEC on November 3, 2026, disclosing a combined holding of 4,300,888 shares of Pyxis Oncology, Inc. common stock …
La-Z-Boy Incorporated filed an 8-K on November 3, 2026, announcing that it will release its Fiscal 2027 Second Quarter financial results for the period ended October 24, 2026, after the close of trading on the New York Stock Exchange on Tuesday, November 17, 2026.
Qatar Investment Authority filed a Schedule 13G with the SEC on November 3, 2026, disclosing a 6.7% beneficial ownership position in Aspen Neuroscience, Inc. (NASDAQ:ASPE) as of an event date of October 30, 2026.
A statement of changes in beneficial ownership was filed on November 3, 2026, disclosing that Frank M. Jaehnert, a director of Nordson Corp, received 583 Restricted Share Units as part of the company's annual non-employee director grant on November 1, 2026.
Canaan Inc. filed an announcement on November 3, 2026, disclosing that it will release its third-quarter 2026 financial results before the U.S. market opens on November 10, 2026, followed by a management conference call the same morning.
Kimberly-Clark Corporation filed an 8-K on November 3, 2026, announcing the final results of its exchange offers for Kenvue LLC notes, with settlement expected on November 4, 2026.
Geospace Technologies Corporation filed an 8-K on November 3, 2026, disclosing that on October 29, 2026, it entered into a new Revolving Loan and Security Agreement with Amerisource Funding, Inc. and simultaneously terminated its existing credit agreement with Woodforest National Bank.
Supernus, Inc. filed a Form 8-K on November 3, 2026, disclosing an increase in the conversion rate of its 0.625% Convertible Senior Notes due 2031 following a Special Dividend declared by its board on September 16, 2026.
PTC Therapeutics, Inc. filed a current report on November 3, 2026, disclosing that its Board of Directors authorized a share repurchase program of up to $500.0 million of the company's common stock.